The Company is set as a “Family and Friends Office” and manages the investments made in companies of the BioHighTech sector as biomedical, biotechnologies and bioinformatics.

The economic operating theatre is Friuli Venezia Giulia region and the neighbouring countries of the AlpeAdria area.

The main activity is in order to accelerate the development and asset value of this high specialized sector.

The Chairman and founder of the company, Diego Bravar, holds the majority of the share capital (1.8 mln € at 31/5/19) with 52.7%. Other significant shareholders are: Friulia Spa with 14.3%, VenetWork which participates through Bio Holding Srl with 15.6%, Dima3 Srl with 5.7%, Marina Pittini con il 3,4%, Samer & Co. Shipping Spa with 2.9%. The remaining 5.4% is held by 10 other shareholders.

The Chairman of the Board of Directors is Diego Bravar, electronic engineer, founder and chairman of TBS Group until 2017, vice-chairman of Confindustria Venezia Giulia.
The Vice President is Paolo Giribona, electronic engineer, professor at the faculty of medicine of the University of Trieste, consultant of the major Italian hospitals and The World Bank, Washington D.C. (Health & Human Development sector).
The members of the Board of Directors are Giulia Bravar, Tiziano Busin, Marino Malvestio, Marina Pittini, Davide Jacur Romanin, Roberta Terpin, Enrico Samer.

The Board of Statutory Auditors is composed of Claudio Sambri, Chairman; and the Statutory Auditors Luca Valentincich and Mario Calligaris.

Diego Bravar – CHAIRMAN

View CV

Paolo Giribona – VICE-PRESIDENT

View CV

The Committee for the analysis and evaluation of investments is chaired by Giovanni Loser, a graduate of Luigi Bocconi in Milan, former general manager of Illycaffè, while the function of Project Manager is headed by Irene Lasorsa, clinical and biomedical engineer.

Giovanni Loser – President of the Investment Committee

View CV

Irene Lasorsa – Project manager

View CV

Paolo Luisi – Commercial consultant

View CV


BioHighTech is an industrial sector with high added value, highly innovative and dynamic, represented by companies operating in the fields of biomedical technologies, biotechnologies, medical information technology and bioinformatics that are strongly linked, with an international turnover of about $ 600 billion (of which about half in biomedical technologies) and growing with percentages ranging from 4% (biomedical technologies) to 7-10% (biotechnologies and medical / bioinformatics information technology). Even in Europe, the market for biomedical technologies (MedTech) alone is worth € 100 billion, growing by 4% per year and includes over 25,000 companies, of which 85% are SME’s. In Friuli Venezia Giulia alone there are about 150 companies in the BioHighTech sector, with a turnover of about € 700 million and an average growth of 4% per year, a result obtained also in recent years of economic crisis. The development of this innovative “regional industrial system” in the health sector has been developed above all by the considerable investments made by the Italian Government in the research bodies of Trieste (about € 300 million per year in the last 30 years) and by other funding in the research and social-health bodies of the FVG Region, which have created a real research system that also operates in the health sector, which is highlighted in this way:

✓ scientific research and training activities carried out in this field by the Universities of Trieste and Udine and by the Scuola Superiore di Studi Avanzati, SISSA of Trieste,

✓ the concentration of regional research institutions of international scope that also operate in this field, such as:

  • Elettra Sincrotrone Trieste, an international multidisciplinary research centre of excellence, specialized in the application of synchrotron radiation and lasers and free electrons in the science of materials, provides industry with all its skills, technological capabilities and products to offer value-added services to support the product and process development of national and foreign companies in the biomedical, pharmaceutical, agri-food and manufacturing sectors;
  • ICGEB Trieste, International Centre for Genetic Engineering and Biotechnology, supported by more than 60 countries including the BRICST countries, is an important access point to the international research system in the field of genetic engineering and in promoting the development of biotechnology products and services in developing countries;

✓ the integrated and multisectoral system of health and social protection of which the Trieste Public Authority for Personal Services, ITIS, as well as the hospitals of Trieste and Udine, are part, together with the scientific research and treatment institutes, Burlo Garofolo of Trieste and CRO of Aviano;

✓ the system integrated by the national science and technology park (Area Science Park of Trieste) which, together with the regional science and technology parks (Technology Pole of Trieste and Pordenone, Science and technology parks of Udine and Amaro), also with the related function of start-up incubator, also operates in the health sector;

✓ the geographical position of Friuli Venezia Giulia and of the other regions of the Alpe Adria area, which allows cross-border and international collaboration, also in the health sector.

The virtuous interaction between the entrepreneurial system of BioHighTech and the system of the University, Research, Training and Regional Social Health finds application in the production of goods and services in the health sector, based on the innovation of the industrial sectors of health (as biomedical, pharmaceutical and/or biopharmaceutical); of the social sector (as domotics and tele-assistance); of the agro-food sector (as nutriceutics); of the environment (as biotechnologies); all linked to a concept of well-being of the population.

The development of innovation in the health sector is also part of the Smart Health programme of intelligent specialisation of the FVG Region and could be speeded up by the intervention of Biovalley Investments S.p.A. which, by providing financial capital, industrial and commercial experience, could encourage interaction between the BioHighTech business system and the research and social-health system operating in the sector in Friuli Venezia Giulia and other neighbouring regions of the Alpe Adria area (Veneto, Trentino Alto Adige, Slovenia, Austria and Croatia), and contribute to accelerating the growth of this highly innovative and dynamic entrepreneurial ecosystem.